Strategic partnerships C2N has active global partnerships in Brazil and Australia to bring PrecivityAD into.memory and brain health care networks, suggesting sales opportunities with large regional hospital groups, labs, and diagnostic distributors seeking blood-based Alzheimer’s testing.

Global expansion Recent collaborations and launches in multiple markets, along with CE Mark and FDA Breakthrough Designation, indicate growing international demand and potential for selling CLIA-certified lab services, adjunct biomarkers, and companion diagnostic opportunities.

Clinical adoption PrecivityAD is designed to aid physicians in evaluating brain amyloid plaques and is ordered through healthcare providers; targeting clinical pathways, neurology and memory clinics can drive high-value test adoption and reimbursement conversations.

Diverse payer readiness Revenue scale and existing funding support indicate readiness to engage payers and hospital networks; opportunities exist to position PrecivityAD as a cost-effective, accessible screening tool within dementia care value-based programs.

complementary tech The mass spectrometry based workflow and CLIA-certified lab readiness present upsell potential for additional brain health biomarkers, analytics services, and ongoing monitoring tests to expand the diagnostic portfolio.